Table 1.
Baseline characteristics of the patients with advanced gastric cancer (n = 65).
| Characteristic | n (%) |
|---|---|
| Age, years | 61.0 ± 11.7, 60.0 (52.0–71.0) |
| Gender (M: F) | 44: 21 |
| BMI | 21.4 ± 3.5, 21.3 (18.6–23.8) |
| Chemotherapy | |
| First | 51 (78.5%) |
| Second | 10 (15.4%) |
| Third | 4 (6.2%) |
| Adjuvant chemotherapy | 23 (47.9) |
| Palliative chemotherapy | 25 (52.1) |
| R resection | |
| R0 | 41 (63.1) |
| R1 | 2 (3.1) |
| R2 | 2 (3.1) |
| HER2+ | 9 (13.8) |
| Prior therapy | |
| Surgery | 52 (80.0) |
| Chemotherapy | 12 (18.5) |
| Surgery and chemotherapy | 1 (1.5) |
| Stage | |
| IIA | 9 (13.8) |
| IIB | 12 (18.5) |
| IIIA | 5 (7.7) |
| IIIB | 5 (7.7) |
| IIIC | 9 (13.8) |
| IV | 25 (38.5) |
| Death | 6 (9.2) |
| Performance | |
| ECOG 0 | 14 (21.5) |
| ECOG 1 | 45 (69.2) |
| ECOG 2 | 6 (9.2) |
BMI, body mass index; HER2/neu, human epidermal growth factor receptor; ECOG,Eastern Cooperative Oncology Group.